11/18
07:20 am
gyre
Gyre Therapeutics (NASDAQ:GYRE) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
Gyre Therapeutics (NASDAQ:GYRE) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/10
06:58 am
gyre
Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 8.6% Concerning? [Yahoo! Finance]
Low
Report
Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 8.6% Concerning? [Yahoo! Finance]
11/7
06:00 am
gyre
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Medium
Report
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
10/18
07:31 am
gyre
Gyre Therapeutics (NASDAQ:GYRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Gyre Therapeutics (NASDAQ:GYRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
10/15
07:00 am
gyre
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
Medium
Report
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
10/14
07:31 am
gyre
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 [Yahoo! Finance]
Low
Report
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 [Yahoo! Finance]
10/14
07:00 am
gyre
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
Medium
Report
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
10/10
07:19 am
gyre
Gyre Therapeutics (NASDAQ:GYRE) was given a new $16.00 price target on by analysts at Jefferies Financial Group Inc..
Medium
Report
Gyre Therapeutics (NASDAQ:GYRE) was given a new $16.00 price target on by analysts at Jefferies Financial Group Inc..
9/5
04:17 pm
gyre
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference [Yahoo! Finance]
Low
Report
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference [Yahoo! Finance]
9/5
04:05 pm
gyre
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Low
Report
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference